News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
459,127 Results
Type
Article (50900)
Company Profile (107)
Press Release (408120)
Section
Business (126248)
Career Advice (1586)
Deals (17977)
Drug Delivery (63)
Drug Development (58499)
Employer Resources (107)
FDA (9877)
Job Trends (10519)
News (213475)
Policy (17590)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (2)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Biotech Bay Standard (3)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (3)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (2)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2761)
Academic (1)
Accelerated approval (3)
Adcomms (12)
Allergies (52)
Alliances (36613)
ALS (66)
Alzheimer's disease (1207)
Antibody-drug conjugate (ADC) (71)
Approvals (9912)
Artificial intelligence (187)
Autoimmune disease (10)
Automation (7)
Bankruptcy (120)
Best Places to Work (8378)
BIOSECURE Act (10)
Biosimilars (36)
Biotechnology (70)
Bladder cancer (40)
Brain cancer (22)
Breast cancer (185)
Cancer (1595)
Cardiovascular disease (117)
Career advice (1301)
Career pathing (21)
CAR-T (114)
Cell therapy (298)
Cervical cancer (14)
Clinical research (46536)
Collaboration (630)
Compensation (74)
Complete response letters (8)
COVID-19 (2111)
CRISPR (29)
C-suite (126)
Cystic fibrosis (74)
Data (1576)
Decentralized trials (2)
Denatured (9)
Depression (32)
Diabetes (150)
Diagnostics (4367)
Digital health (13)
Diversity (7)
Diversity, equity & inclusion (28)
Drug discovery (95)
Drug pricing (74)
Drug shortages (9)
Duchenne muscular dystrophy (43)
Earnings (45056)
Editorial (19)
Employer branding (14)
Employer resources (93)
Events (59141)
Executive appointments (423)
FDA (10623)
Featured Employer (25)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (7)
Funding (485)
Gene editing (63)
Generative AI (16)
Gene therapy (198)
GLP-1 (439)
Government (2831)
Grass and pollen (4)
Guidances (35)
Healthcare (13867)
Huntington's disease (10)
IgA nephropathy (14)
Immunology and inflammation (54)
Indications (19)
Infectious disease (2215)
Inflammatory bowel disease (95)
Inflation Reduction Act (7)
Influenza (39)
Intellectual property (56)
Interviews (302)
IPO (8397)
IRA (40)
Job creations (2465)
Job search strategy (1132)
Kidney cancer (6)
Labor market (21)
Layoffs (273)
Leadership (9)
Legal (3091)
Liver cancer (50)
Lung cancer (229)
Lymphoma (109)
Machine learning (3)
Management (35)
Manufacturing (178)
MASH (48)
Medical device (8026)
Medtech (8029)
Mergers & acquisitions (9915)
Metabolic disorders (376)
Multiple sclerosis (55)
NASH (13)
Neurodegenerative disease (58)
Neuropsychiatric disorders (15)
Neuroscience (1573)
NextGen: Class of 2025 (4554)
Non-profit (4171)
Northern California (1573)
Now hiring (22)
Obesity (177)
Opinion (149)
Ovarian cancer (65)
Pain (49)
Pancreatic cancer (55)
Parkinson's disease (101)
Partnered (15)
Patents (124)
Patient recruitment (82)
Peanut (32)
People (36302)
Pharmaceutical (28)
Pharmacy benefit managers (6)
Phase I (14427)
Phase II (20402)
Phase III (15317)
Pipeline (871)
Podcasts (27)
Policy (92)
Postmarket research (2056)
Preclinical (7100)
Press Release (68)
Prostate cancer (67)
Psychedelics (24)
Radiopharmaceuticals (174)
Rare diseases (235)
Real estate (4738)
Recruiting (40)
Regulatory (12979)
Reports (28)
Research institute (2541)
Resumes & cover letters (242)
Rett syndrome (1)
RNA editing (1)
RSV (30)
Schizophrenia (50)
Series A (70)
Series B (44)
Service/supplier (11)
Sickle cell disease (45)
Southern California (1339)
Special edition (13)
Spinal muscular atrophy (111)
Sponsored (23)
Startups (2416)
Stomach cancer (5)
Supply chain (34)
Tariffs (7)
The Weekly (17)
United States (13824)
Vaccines (545)
Venture capitalists (12)
Webinars (11)
Weight loss (104)
Women's health (18)
Worklife (9)
Date
Today (67)
Last 7 days (490)
Last 30 days (1835)
Last 365 days (22350)
2025 (5364)
2024 (23405)
2023 (27059)
2022 (36960)
2021 (39261)
2020 (37115)
2019 (32273)
2018 (24390)
2017 (21664)
2016 (21699)
2015 (25444)
2014 (19320)
2013 (17092)
2012 (17397)
2011 (18111)
2010 (16636)
Location
Africa (602)
Alabama (40)
Alaska (5)
Arizona (114)
Arkansas (8)
Asia (28247)
Australia (5056)
California (3539)
Canada (1200)
China (357)
Colorado (166)
Connecticut (162)
Delaware (79)
Europe (63452)
Florida (562)
Georgia (139)
Idaho (29)
Illinois (333)
India (21)
Indiana (194)
Iowa (5)
Japan (118)
Kansas (58)
Kentucky (20)
Louisiana (9)
Maine (19)
Maryland (552)
Massachusetts (2504)
Michigan (155)
Minnesota (208)
Mississippi (1)
Missouri (52)
Montana (20)
Nebraska (15)
Nevada (28)
New Hampshire (34)
New Jersey (1142)
New Mexico (26)
New York (1188)
North Carolina (650)
North Dakota (5)
Northern California (1573)
Ohio (134)
Oklahoma (10)
Oregon (20)
Pennsylvania (774)
Puerto Rico (3)
Rhode Island (18)
South America (718)
South Carolina (12)
Southern California (1339)
Tennessee (70)
Texas (543)
Utah (98)
Virginia (88)
Washington D.C. (47)
Washington State (365)
West Virginia (2)
Wisconsin (32)
459,127 Results for "palo alto research center".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Xerox Announces Donation of Palo Alto Research Center (PARC) to SRI International
Xerox Holdings Corporation announced the donation of the Palo Alto Research Center to SRI International, a nonprofit research institute behind some of the world’s most impactful deep tech advancements.
April 24, 2023
·
4 min read
Biotech Bay
Mispro to Expand Contract Vivarium Network to Palo Alto
Innovative contract vivarium organization, Mispro, plans to expand its vivarium research labs network to Palo Alto’s prestigious Stanford Research Park.
May 18, 2023
·
2 min read
Press Releases
Sai Life Sciences sets up Peptide Research Center in India
April 3, 2025
·
2 min read
Press Releases
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights
March 20, 2025
·
15 min read
Press Releases
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
February 19, 2025
·
3 min read
Press Releases
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
February 13, 2025
·
6 min read
Neuroscience
Alto Depression Therapy Fails Mid-Stage Trial, 9 Months After IPO
Alto Neuroscience’s depression treatment failed to beat placebo just nine months after the biotech went public. The stunning failure called to mind Acelyrin, which faced a similar fate last year.
October 23, 2024
·
4 min read
·
Annalee Armstrong
Press Releases
Alto Neuroscience to Participate in Upcoming March 2025 Investor Conferences
February 26, 2025
·
1 min read
Press Releases
START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center
START’s Site Network Solidifies its Global Leadership in Urological Cancer Trials
March 20, 2025
·
1 min read
Drug Development
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ALTO-101, a novel PDE4 inhibitor in development for the treatment of cognitive impairment associated with schizophrenia (CIAS).
June 20, 2024
·
6 min read
1 of 45,913
Next
